All patients | Patients with MI | Patients without MI | |
No of patients | 8432 | 84 | 8348 |
Age, years (SD) | 61.7 (12.7) | 66.5 (12.3) | 61.7 (12.7) |
Women, n (%) | 4163 (49) | 29 (35) | 4134 (50) |
Index visit data | |||
0-hour hs-cTnT concentration (ng/L), median (IQR) | 6.0 (3.3) | 8.8 (3.6) | 6.0 (3.3) |
Delta hs-cTnT (ng/L), mean (SD)* | 0.4 (4.9) | 13.8 (20.0) | 0.3 (4.3) |
Early retest (45 min to <2 hours), n (%) | 3847 (46) | 26 (31) | 3821 (46) |
Late retest (2 hours to ≤3.5 hours), n (%) | 4585 (54) | 58 (69) | 4527 (54) |
Time from 0-hour hs-cTnT to second hs-cTnT measurement, min, median (IQR) | 133 (101) | 175 (94) | 132 (101) |
Early retest group (45 min to <2 hours), n (%) | 77 (27) | 75 (31) | 77 (27) |
Late retest group (2 to ≤3.5 hours), n (%) | 179 (28) | 181 (18) | 178 (28) |
Historical hs-cTnT concentration (ng/L), median (IQR) | 6.3 (4.6) | 9.0 (11.8) | 6.3 (4.5) |
Time from historical hs-cTnT to 0-hour hs-cTnT measurement, days, median (IQR) | 207 (464) | 169 (531) | 208 (463) |
Comorbidities | |||
Prior stroke, n (%) | 506 (6.0) | 3 (3.6) | 503 (6.0) |
Prior MI, n (%) | 2017 (24) | 44 (52) | 1973 (24) |
COPD, n (%) | 538 (6.4) | 6 (7.1) | 532 (6.4) |
Prior heart failure, n (%) | 345 (4.1) | 3 (3.6) | 342 (4.1) |
Diabetes, n (%) | 1012 (12) | 23 (27) | 989 (12) |
Chronic kidney disease (eGFR <60 mL/min/1.73 m2), n (%) | 65 (0.8) | 2 (2.4) | 63 (0.8) |
Peripheral arterial disease, n (%) | 90 (1.1) | 6 (7.1) | 84 (1.0) |
Prior coronary angiography, n (%) | 3100 (37) | 53 (63) | 3047 (37) |
Prior revascularisation, n (%) | 2375 (28) | 44 (52) | 2331 (28) |
Medication | |||
Aspirin, n (%) | 3046 (36) | 51 (61) | 2995 (36) |
P2Y12 inhibitor†, n (%) | 1243 (15) | 27 (32) | 1216 (15) |
Beta-blockers, n (%) | 3930 (47) | 57 (68) | 3873 (46) |
ACE/ARB, n (%) | 3635 (43) | 50 (60) | 3585 (43) |
Statins, n (%) | 3450 (41) | 53 (63) | 3397 (41) |
OAC, n (%) | 1030 (12) | 9 (11) | 1021 (12) |
Warfarin, n (%) | 687 (8.1) | 8 (9.5) | 679 (8.1) |
NOAC, n (%) | 383 (4.5) | 2 (2.4) | 381 (4.6) |
*Delta hs-cTnT between the 0-hour hs-cTnT and second hs-cTnT measurements.
†P2Y12 inhibitor, including clopidogrel, ticagrelor or prasugrel.
ACEi/ARB, ACE inhibitor/angiotensin receptor blocker; COPD, chronic obstructive pulmonary disease; hs-cTn, high-sensitivity cardiac troponin; MI, myocardial infarction; NOAC, new oral anticoagulant; OAC, oral anticoagulants.